Journal article
Predictors of consent to pharmacogenomics testing in the IDEAL study
Alison B Jazwinski, Paul J Clark, Alexander J Thompson, Stuart C Gordon, Eric J Lawitz, Stephanie Noviello, Clifford A Brass, Lisa D Pedicone, Janice K Albrecht, Mark S Sulkowski, Andrew J Muir
PHARMACOGENETICS AND GENOMICS | LIPPINCOTT WILLIAMS & WILKINS | Published : 2013
Abstract
INTRODUCTION: Pharmacogenomic testing is important in developing individualized therapeutic approaches. In the phase 3 IDEAL (Individualized Dosing to Assess Optimal Pegylated Interferon Therapy) clinical trial, a subset of patients receiving peginterferon and ribavirin for treatment of chronic hepatitis C agreed to provide blood samples for genetic testing. Genome-wide association studies subsequently identified associations between IL28B polymorphism and sustained virologic response, and ITPA polymorphism and ribavirin-associated anemia. OBJECTIVE: To characterize the groups of patients who accepted or declined pharmacogenomic testing in the IDEAL study. METHODS: Clinical and demographic f..
View full abstractGrants
Awarded by Duke Training Grant in Digestive Diseases and Nutrition
Awarded by NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
Funding Acknowledgements
The IDEAL study was sponsored by Schering-Plough (now Merck & Co. Inc.).Editorial assistance was provided by Tim Ibbotson, PhD, and Bianca Ruzicka, PhD, of ApotheCom (Yardley, PA). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., Whitehouse Station, NJ.A.B.J. received the Duke Training Grant in Digestive Diseases and Nutrition during the period from 1 July 2010 to 30 June 2011 (#NIH 5T32DK007568-20).